Last reviewed · How we verify
Recombinant Human Albumin Injection
Recombinant human albumin acts as a plasma volume expander and carrier protein to maintain oncotic pressure and transport endogenous substances.
Recombinant human albumin acts as a plasma volume expander and carrier protein to maintain oncotic pressure and transport endogenous substances. Used for Hypovolemia and shock management, Plasma protein replacement in critical illness, Albumin deficiency states.
At a glance
| Generic name | Recombinant Human Albumin Injection |
|---|---|
| Also known as | Intravenous infusion of human albumin injection, Intravenous infusion of recombinant human albumin injection |
| Sponsor | The First Hospital of Jilin University |
| Drug class | Plasma volume expander; recombinant protein therapeutic |
| Modality | Small molecule |
| Therapeutic area | Critical Care; Hematology |
| Phase | Phase 3 |
Mechanism of action
Recombinant human albumin is a recombinantly produced version of the most abundant plasma protein. It functions to restore and maintain intravascular oncotic pressure, expand plasma volume in hypovolemic states, and serve as a carrier for various endogenous and exogenous substances. It is used as a therapeutic agent in conditions requiring volume replacement and protein supplementation.
Approved indications
- Hypovolemia and shock management
- Plasma protein replacement in critical illness
- Albumin deficiency states
Common side effects
- Fever
- Chills
- Nausea
- Hypersensitivity reactions
- Hypervolemia
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials (EARLY_PHASE1)
- Phase II/III of Recombinant Human Serum Albumin (PHASE2, PHASE3)
- Belimumab With Rituximab for Primary Membranous Nephropathy (PHASE2)
- A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer (PHASE1)
- A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites (PHASE3)
- QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (PHASE1, PHASE2)
- Phase II/III of Recombinant Human Albumin Injection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: